Feb 29 (Reuters) - Ironwood Pharmaceuticals said on Thursday that its treatment for a type of bowel disease met the main goal in a late-stage trial. (Reporting by Christy Santhosh; Editing by Savio D'Souza)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.88 USD | -1.18% | -13.27% | -48.60% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-48.60% | 935M | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+38.17% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |
- Stock Market
- Equities
- IRWD Stock
- News Ironwood Pharmaceuticals, Inc.
- Ironwood says bowel disease treatment meets main goal in late-stage trial